Table 2 |
||
| Multivariate Cox regression analysis of clinicopathological parameters and aquaporin 3 protein expression by the tumour regarding recurrence free (a), progression-free (b) and cancer-specific survival (c) in stage T1 urothelial bladder carcinoma | ||
| HR (CI 95%) | p-value | |
| a. | ||
| Genderfemale vs. male | 0.50 (0.11 – 2.29) | 0.372 |
| Ageper year | 1.01 (0.97 – 1.05) | 0.770 |
| Recurrent diseaseyes vs. no (initial finding) | 0.58 (0.10 – 3.50) | 0.552 |
| Grading WHO 1973G3 vs. G2 | 1.08 (0.25 – 4.67) | 0.916 |
| Associated CISyes vs. no | 1.58 (0.63 – 3.97) | 0.328 |
| Focalitymultifocal vs. unifocal | 0.33 (0.07 – 1.65) | 0.177 |
| Tumour size≥3cm vs. <3cm | 0.68 (0.25 – 1.92) | 0.485 |
| BCG instillations≤6 vs. >6 | 0.77 (0.23 – 2.57) | 0.667 |
| AQP3negative vs. positive expression | 0.81 (0.29 – 2.25) | 0.552 |
| b. | ||
| Genderfemale vs. male | 0.42 (0.03 – 5.27) | 0.500 |
| Ageper year | 1.01 (0.95 – 1.08) | 0.697 |
| Recurrent diseaseyes vs. no (initial finding) | 4.08 (0.24 – 69.74) | 0.332 |
| Grading WHO 1973G3 vs. G2 | 0.71 (0.28 – 1.79) | 0.469 |
| Associated CISyes vs. no | 1.40 (0.28 – 7.12) | 0.683 |
| Focalitymultifocal vs. unifocal | constant | 0.976 |
| Tumour size≥3cm vs. <3cm | 2.64 (0.30 – 22.97) | 0.380 |
| BCG instillations≤6 vs. >6 | constant | 0.977 |
| AQP3negative vs. positive expression | 7.58 (1.29 – 44.68) | 0.025 |
| c. | ||
| Genderfemale vs. male | constant | 0.972 |
| Ageper year | 1.03 (0.97 – 1.09) | 0.338 |
| Recurrent diseaseyes vs. no (initial finding) | constant | 0.999 |
| Grading WHO 1973G3 vs. G2 | constant | 0.975 |
| Associated CISyes vs. no | 0.79 (0.18 – 3.46) | 0.756 |
| Focalitymultifocal vs. unifocal | constant | 0.976 |
| Tumour size≥3cm vs. <3cm | 2.98 (0.35 – 24.86) | 0.316 |
| BCG instillations≤6 vs. >6 | constant | |
| AQP3negative vs. positive expression | 1.16 (0.26 – 5.15) | 0.849 |
Reference in italics; p-values <0.05 are indicated in bold; AQP3 aquaporin 3 protein; BCG Bacillus Calmette-Guérin; CI confidence interval; CIS carcinoma in situ; HR hazard ratio; WHO world health organisation.
Otto et al. BMC Cancer 2012 12:459 doi:10.1186/1471-2407-12-459
